




PHARMACEUTICAL 2022

Dianthus Therapeutics Inc. DE
Rank 121 of 466





RealRate

PHARMACEUTICAL 2022

Dianthus Therapeutics Inc. DE Rank 121 of 466



The relative strengths and weaknesses of Dianthus Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Dianthus Therapeutics Inc. DE is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 140% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	180,693
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,863
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	-7.0
Other Expenses	0
Other Liabilities	6,399
Other Net Income	0
Other Revenues	3,556
Property and Equipment	7,461
Research and Development	46,766
Selling, General and Administrative Expense	27,926

Output Variable	Value in 1000 USD
Assets	189,934
Liabilities	17,262
Expenses	74,692
Revenues	3,556
Stockholders Equity	172,672
Net Income	-71,136
Comprehensive Net Income	-71,140
Economic Capital Ratio	218%